Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
StandardStandard
Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost? / Hughes, D.; Hughes, D.A.
2006. Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany.
2006. Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
HarvardHarvard
Hughes, D & Hughes, DA 2006, 'Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?', Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany, 3/01/01.
APA
Hughes, D., & Hughes, D. A. (2006). Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?. Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany.
CBE
Hughes D, Hughes DA. 2006. Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?. Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany.
MLA
Hughes, D. a D.A. Hughes Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?. 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany, 03 Ion 0001, Papur, 2006.
VancouverVancouver
Hughes D, Hughes DA. Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?. 2006. Papur a gyflwynwyd yn 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany.
Author
RIS
TY - CONF
T1 - Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?
AU - Hughes, D.
AU - Hughes, D.A.
PY - 2006/11/1
Y1 - 2006/11/1
M3 - Paper
T2 - 10th European Sympoisum on Patient Compliance and Persistence, Bonn, Germany
Y2 - 3 January 0001
ER -